Cetera Investment Advisers Buys New Shares in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Cetera Investment Advisers purchased a new stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 10,092 shares of the specialty pharmaceutical company's stock, valued at approximately $1,243,000.

Other large investors have also recently bought and sold shares of the company. Moloney Securities Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $464,000. BTC Capital Management Inc. increased its position in Jazz Pharmaceuticals by 9.4% during the 4th quarter. BTC Capital Management Inc. now owns 49,653 shares of the specialty pharmaceutical company's stock worth $6,115,000 after buying an additional 4,271 shares during the period. Summit Trail Advisors LLC bought a new position in Jazz Pharmaceuticals during the 4th quarter worth $539,000. Atria Investments Inc lifted its holdings in shares of Jazz Pharmaceuticals by 19.5% during the fourth quarter. Atria Investments Inc now owns 2,732 shares of the specialty pharmaceutical company's stock worth $336,000 after buying an additional 445 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its position in shares of Jazz Pharmaceuticals by 5.5% in the fourth quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company's stock valued at $272,713,000 after acquiring an additional 115,102 shares during the period. 89.14% of the stock is owned by institutional investors.

Analyst Ratings Changes

JAZZ has been the subject of several analyst reports. Truist Financial lifted their price objective on shares of Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a "buy" rating in a research note on Thursday, March 6th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and boosted their price target for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Robert W. Baird lowered their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. JPMorgan Chase & Co. lifted their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, Barclays reissued an "overweight" rating and set a $200.00 target price (up from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Two analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $182.79.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded down $0.72 during midday trading on Wednesday, reaching $108.75. 92,631 shares of the company were exchanged, compared to its average volume of 1,081,742. The stock's 50-day moving average price is $111.57 and its 200-day moving average price is $121.78. The stock has a market cap of $6.70 billion, a P/E ratio of 15.32, a PEG ratio of 1.04 and a beta of 0.38. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a one year low of $95.49 and a one year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a net margin of 11.60% and a return on equity of 29.30%. The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same period last year, the business earned $2.68 EPS. The company's revenue was down .5% compared to the same quarter last year. On average, sell-side analysts anticipate that Jazz Pharmaceuticals plc will post 16.96 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Neena M. Patil sold 3,800 shares of the firm's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the transaction, the executive vice president now owns 33,318 shares of the company's stock, valued at approximately $4,826,778.66. This trade represents a 10.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Bruce C. Cozadd sold 6,500 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $144.25, for a total value of $937,625.00. Following the completion of the sale, the chief executive officer now owns 464,058 shares of the company's stock, valued at $66,940,366.50. The trade was a 1.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,236 shares of company stock valued at $3,956,190 over the last quarter. 4.20% of the stock is owned by company insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.